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Background: Epigenetic alterations of specific genes have been reported to be related to colorectal cancer (CRC)
transformation and would also appear to be involved in the early stages of colorectal carcinogenesis. Little data are
available on the role of these alterations in determining a different risk of colorectal lesion recurrence. The aim of
the present study was to verify whether epigenetic alterations present in pre-neoplastic colorectal lesions detected
by colonoscopy can predict disease recurrence.
Methods: A retrospective series of 78 adenomas were collected and classified as low (35) or high-risk (43) for
recurrence according to National Comprehensive Cancer Network guidelines. Methylation alterations were analyzed
by the methylation-specific multiplex ligation probe assay (MS-MLPA) which is capable of quantifying methylation
levels simultaneously in 24 different gene promoters. MS-MLPA results were confirmed by pyrosequencing and
immunohistochemistry.
Results: Higher levels of methylation were associated with disease recurrence. In particular, MLH1, ATM and FHIT gene
promoters were found to be significantly hypermethylated in recurring adenomas. Unconditional logistic regression
analysis used to evaluate the relative risk (RR) of recurrence showed that FHIT and MLH1 were independent variables
with an RR of 35.30 (95% CI 4.15-300.06, P = 0.001) and 17.68 (95% CI 1.91-163.54, P = 0.011), respectively.
Conclusions: Histopathological classification does not permit an accurate evaluation of the risk of recurrence of
colorectal lesions. Conversely, results from our methylation analysis suggest that a classification based on molecular
parameters could help to define the mechanisms involved in carcinogenesis and prove an effective method for
identifying patients at high risk of recurrence.
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Pre-neoplastic lesion classificationBackground
Colorectal cancer (CRC), a disease arising from complex
and heterogeneous etiological factors and pathogenetic
mechanisms, develops in a multi-step manner from normal
epithelium, through a pre-malignant lesion (adenoma), into
a malignant lesion (carcinoma) [1]. Histopathological evalu-
ation of early stage CRC in many cases reveals areas of* Correspondence: daniele.calistri@irst.emr.it
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unless otherwise stated.adenomatous mucosa, but the presence of tissue with histo-
logical features ranging from pure tubular to pure villous
adenomas accompanied by dysplasia is also frequently
detected in invasive colorectal cancer [1,2]. Although indi-
viduals with syndromes that strongly predispose to aden-
omas, e.g. familial adenomatous polyposis (FAP), invariably
develop CRC by the third to fifth decade of life if these
lesions are not removed [3], most adenomas (not FAP) have
a low risk of progressing into cancer (about 5%) if not
resected. An adenomatous polyp is a much more frequent
finding than CRC and polypectomy has a distinctly protectiveal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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been estimated that in the first 10 years after polypec-
tomy, the risk of CRC is reduced to a level similar to
that of individuals whose colonoscopy does not reveal
the presence of polyps [4,5].
Different molecular mechanisms seem to be related to
CRC development. The vast majority of tumors (about
50-80%), present chromosomal instability (CIN) [3,6,7],
while a smaller fraction (10-15%) is characterized by
microsatellite instability (MSI) [3,6,7]. In recent years,
epigenetic alterations have gained recognition as a key
mechanism in carcinogenesis. In particular, hyper-
methylation of CpG islands present in gene promoter
sequences leads to the inactivation of tumor suppres-
sor genes, working in a different way with respect to
genetic mutations [8,9].
This aberrant methylation status occurs at the same
time as genetic alterations which drive the initiation and
progression of colorectal cancer, suggesting that methy-
lation plays an important role in many stages of tumor
transformation [10-14]. The existence of a methylator
phenotype could be related to distinctive biological and/
or clinical characteristics [15].
CRCs that show hypermethylation changes in numerous
different CpG-rich DNA regions are defined as showing
the CpG island methylator phenotype (CIMP) [16].
CIMP-positive cancers have distinct clinical pathological
characteristics such as proximal colon location, mucinous
and poorly differentiated histology, female preponderance
and older age [17]. This phenotype also seems to be asso-
ciated with MSI and BRAF mutations [18,19]. Conversely,
hypomethylation of specific sequences may decrease the
fidelity of chromosomal segregation [20], suggesting that it
may be involved in the chromosomal instability phenotype
[21]. DNA methylation changes probably lead adenoma-
tous precursor lesions to progress into malignant tumors.
In fact, sessile serrated adenomas, considered important
precursors of cancer, are often CIMP-positive.
Taking the above considerations into account, a better
understanding of the epigenetic mechanisms associated
with adenoma-carcinoma transition could represent an
important tool for CRC prevention. In accordance with
international guidelines, pre-neoplastic lesions of the
colon and rectum are classified according to pathological
parameters (size, histology, number of polyps and dys-
plasia) as having high or low risk of recurrence. In high
risk patients a new colonoscopy is performed after
3 years, while in low risk subjects the time interval is
extended to 5 years. However, this type of subdivision is
unable to predict the real risk of developing a new
lesion. In fact, it has been seen that patients who are
classified as high risk may not experience any further
problems, while those who are classed as low risk may
relapse after a short time.Little data is available on the relationship between risk
of recurrence of pre-neoplastic lesions and molecular
alterations of colorectal lesions, whereas a great deal is
known about the mechanisms of CRC transformation. Al-
though a number of gene promoter methylation profiles
have been shown to characterize specific stages of tumor
progression, no data are available on epigenetic alterations
or risk of disease evolution/recurrence. The identification
of these specific epigenetic profiles could help us to better
understand the mechanisms of adenoma recurrence and,
possibly, adenoma-carcinoma transition, resulting in a
more accurate classification of the risk of recurrence of
pre-neoplastic and permitting a personalized program of
cancer prevention.
The aim of this study was to evaluate whether altered
methylation profiles in pre-neoplastic lesions sampled by
colonoscopy is capable of identifying patients at high risk
of recurrence with greater accuracy than conventional
clinical pathological parameters.
Methods
Case series
We evaluated formalin fixed paraffin-embedded (FFPE) tis-
sue samples of pre-neoplastic colorectal lesions endoscopic-
ally identified and surgically removed from a series of 78
patients who underwent follow up for at least 5 years.
Lesions were classified as adenomas at low risk (3 tubular
polyps with a diameter < 1 cm) or high risk (high-risk dyspla-
sia, > 3 adenomatous villous or tubulovillous polyps, at least
one of which with a diameter of ≥ 1 cm, or an in situ carci-
noma) of recurrence according to National Comprehensive
Cancer Network guidelines. All tissue samples were obtained
from the Pathology Unit of Morgagni-Pierantoni Hospital
(Forlì, Italy). Informed consent for the use of biological sam-
ples was obtained from all individuals who agreed to take
part in the study for research purposes. The study protocol
was reviewed and approved by the IRST Ethics Committee.
DNA extraction
DNA was extracted using a digestion buffer (50 mM KCl,
10 mM Tris–HCl pH8, 2.5 mM MgCl2, 0.45% v/v
TWEEN-20 and proteinase K 25 mg/ml). Approximately
three 5-μm slices of paraffin-embedded tissue was added
to 150 ml of home-made buffer and 10 ml of proteinase K
(25 mg/ml). After overnight incubation at 58°C with gentle
shaking, the sample was heated to 98°C for 10 min, cooled
to room temperature and then centrifuged at 6000 rpm
for 10 min. The supernatant containing DNA was trans-
ferred to a new vial and centrifuged again as per the previ-
ous step until all traces of paraffin were removed. The
quality and quantity of DNA were assessed using Nano-
Drop ND-1000 (Thermo Fisher Scientific, Waltham, USA)
and the DNA was stored at −20°C until molecular analysis
was performed.
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Methylation-specific multiplex ligation probe analysis
Methylation-specific (MS) multiplex ligation probe ana-
lysis (SALSA MLPA ME001 Tumour Suppressor-1 kit,
MLPA®; MRC-Holland, Amsterdam, The Netherlands), a
high-throughput, semi-quantitative, methylation-specific
enzyme-based polymerase chain reaction (PCR) assay, was
performed according to the manufacturer’s instructions.
Each probe corresponded to a single gene, apart from
MLH1 and RASSF1, both of which contained two probes.
Two ligation probe reactions were needed to calculate the
percentage of methylation, one of which contained the
methylation-sensitive enzyme HhaI. Briefly, 200 ng of each
sample was diluted to 5 μl with TE buffer and heated at
98°C for 10 min followed by incubation at 25°C for 5 min
in a thermocycler. Following the addition of ligation
probes, samples were first incubated at 98°C for 1 min and
then at 60°C for 16–18 h to permit hybridization. Samples
were split equally into two vials, each containing the same
amount of DNA (volume 10 ul). Ligase-65 mix (Ligase-65
buffer, Ligase-65 enzyme and water) was added to the first
vial, and Ligase-Digestion mix (Ligase-65 buffer, Ligase-
65 enzyme, HhaI enzyme [Promega, Southampton, UK]
and water) to the second.
Both samples were incubated at 49°C for 30 min, after
which the ligase enzyme was inactivated by heating at 98°C
for 5 min. PCR buffer, deoxynucleoside 5-triphosphates
(dNTPs) and Taq polymerase were added to the samples
during preheating at 72°C. The PCR reaction was
performed in a thermocycler preheated to 72°C, under the
following conditions: 35 cycles at 95°C for 30 s, 60°C for
30 s and 72°C for 60 s. The final incubation was at 72°C for
20 min. Amplification products were analyzed on an ABI-
3130 DNA Analyzer (Applied Biosystems, Warrington,
UK). Negative water controls were included to ensure no
contamination. Internal validation was performed using
unmethylated and methylated genomic DNA (Millipore,
Watford, UK).
Intrasample normalization was performed to address
peak variations due to fluctuations in the assay run, such
as amount of DNA, ploidy variations and PCR condi-
tions, The relative peak height of each probe was deter-
mined by dividing the absolute peak height by the mean
height of all 15 control probes. A methylation percen-
tage for each probe was obtained using the following
calculation, as described previously [22]:
Methylation %ð Þ ¼ peakheightof agivenprobe=meanheightof controlprobesð Þwith Hha1
peakheightof agivenprobe=meanheightof controlprobesð Þwithout Hha1
 100
Validation of MS-MLPA results
Validation of MS-MLPA results was only performed for
the three most significant genes: ATM, FHIT and MLH1.
ATM and MLH1 were confirmed by pyrosequencing CpGanalysis, while FHIT was validated by immunohistochem-
istry (IHC) staining.
Twenty microliters of extracted DNA were converted
using Epitect Bisulphite kit (Qiagen, Hilden, Germany) in
accordance with the “Sodium Bisulphite Conversion of
Unmethylated Cytosines in DNA” protocol. Converted
DNA was eluted in 20 μl of elution buffer. Five microliters
of bisulphite-treated DNA were used to amplify the
specific promoter regions of ATM and MLH1 genes with
primer sets designed to amplify the same CpG sites as
those of the MS-MLPA approach. Primer sets for amplifi-
cation and sequencing were designed by Diatech Pharma-
cogenetics (Jesi, Italy) (Table 1).
Each PCR reaction was performed in a final volume of
50 μl containing 2 μl of each primer (5 μM), 1 μl of Takara
dNTP mixture (10 mM of each dNTP) (Takara Bio Inc.,
Otsu, Japan), 1 μl of Takara 50 mM Mg++ solution (Takara
Bio Inc.), 2.5 μl of EvaGreen™ Dye (20X), 10 μl of Takara
5X R-PCR Buffer (Mg++ free) (Takara Bio Inc.), 0.5 μl of
Takara Ex Taq™ HS (5 U/μl) (Takara Bio Inc.), 26 μl of
water and 5 μl of bisulphite-treated DNA. Amplification
was done by quantitative Real Time PCR on Rotor Gene™
6000 (Corbett Life Science, Cambridge, UK) equipped with
Rotor Gene 6000 Series Software 1.7 Build 87. The cycling
programme for ATM and MLH1 consisted of one hold
cycle at 95°C for 5 min, the second hold cycle at 72°C for
5 min, one pre-melting cycle at 65°C for 90 s and then one
melting cycle from 65°C to 95°C with an increase of 1°C
every 5 s, with fluorescence acquisition. Between the first
two holding cycles there were 45 cycles. For ATM gene,
these cycles consisted of: denaturation at 95°C for 30 s,
annealing 56°C for 30 s and elongation 72°C for 20 s. For
MLH1, the 45 cycles comprised denaturation at 95°C for
30 s, annealing at 56°C for 60 s and an elongation cycle at
72°C for 30 s.
Promoter CpG sites were analyzed by PyroQ-CpG™
1.0.9 software (Biotage, Uppsala, Sweden) on Pyromark
Q96 ID (Qiagen). 40 μl of PCR products were added to
37 μl of binding buffer and 3 μl of Sepharose beads and
mixed at 1400 rpm for 10 min at room temperature.
The Sepharose beads with single-stranded templates
attached were released into a plate containing an anneal-
ing mixture composed of 38.4 μl of annealing buffer and
1.6 μl of the corresponding sequencing primers. All the
experimental procedures were carried out according to
the manufacturer’s instructions. We added water as
negative control and universal methylated and unmethy-
lated samples as positive control.
Four-μm-thick FFPE adenoma sections were used for
immunodetection. Sections were deparaffinized in xylene
and dehydrated in a graded alcohol series, according to
the local protocol. Antigen retrieval was achieved by
microwaving in 10 mM of sodium citrate buffer at pH 6
for 30 min. Sections were incubated with rabbit polyclonal
Table 1 Validation of MS-MLPA results for ATM, MLH1 and FHIT
Gene Method Primer sequence/polyclonal antibody No. samples examined Overall concordance (%)
ATM Pyrosequencing CpG analysis Fw: 5′-AGAAGTGGGAGTTGGGTAGTT-3′ 77/78 73%
Rv: 5′-biotinCTCCCCCCCCCTACCACTACACTC-3′
Seq: 5′-AGGAGGAGAGAGGAGT-3′
MLH1 Pyrosequencing CpG analysis Fw: 5′-biotinGGGAGGTAAGTTTAAGTGGAATAT-3′ 72/78 79%
Rv: 5′-CCAATCCCCACCCTAAAACCCTC-3′
Seq: 5′-CTAAACTCCCAAATAATAACCT-3′
FHIT Immunohistochemistry Rabbit polyclonal anti-FHIT; clone PA1-37690;
Thermo Scientific Pierce; working dilution: 1/200
57/78 84%
Abbreviations: Fw Forward Primer, Rv Reverse primer, Seq sequence analyzed.
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Waltham, USA) at a 1/200 working dilution. From this
point onwards, all the steps were performed automati-
cally by Autostainer Plus Staining System (Dako Cyto-
matic, Glostrop, Denmark). LSAB protein block (Dako;
Carpinteria, USA) was performed for 15 min. The staining
of the primary antibody was performed for 130 min.
Sections were immunostained with anti-rabbit biotinylated
secondary antibody LSAB (Dako) for 10 min. Visualization
was performed using DAB chromogen (Dako). SectionsTable 2 Clinical pathological characteristics of the case series
Total n (%) Disease rec
Gender
Male 56 (71.8) 24 (77.4)
Female 22 (28.2) 7 (22.6)
Median age, years (range)
Male 61 (42–85) 64 (48–85)
Female 66 (40–81) 63 (51–72)
Risk of recurrence
High risk 43 (55.1) 16 (51.6)
Low risk 35 (44.9) 15 (48.4)
Dysplasia
Low (low and medium) grade 61 (78.2) 26 (83.9)
High grade 17 (21.8) 5 (16.1)
Lesion dimension
0–0.9 cm 9 (11.5) 3 (9.7)
≥ 1 cm 29 (37.2) 11 (35.5)
Not specified 40 (51.3) 17 (54.8)
Lesion localization
Ascending colon 19 (24.4) 10 (32.3)
Descending colon 37 (47.4) 9 (29.0)
Mixed 22 (28.2) 12 (38.7)
Adenoma morphology
Tubular 46 (59.0) 19 (61.3)
Villous 3 (3.8) 0
Tubulovillous (mixed) 29 (37.2) 12 (38.7)were counterstained with hematoxylin, dehydrated in the
same graded alcoholic scale and mounted. On the basis of
antibody datasheet instructions, negative and positive
control sections were incubated with the secondary antibody
in the presence or not of the primary antibody, respectively.
Statistical analysis
In order to evaluate the correlation between methylation
status and prognosis for adenoma/disease recurrence,
patients were subdivided into relapsed (R) or noturrence n (%) No. of disease recurrence n (%) P
32 (68.1)
15 (31.9) 0.523
61 (42–79) 0.263
66 (40–81) 0.972
27 (57.4)
20 (42.6) 0.784
35 (74.5)
12 (25.5) 0.481
6 (12.8)
18 (38.3)
23 (48.9) 1.000
9 (19.1)
28 (59.6)
10 (21.3) 0.015
27 (57.4)
3 (6.4)
17 (36.2) 0.441
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ship between clinical pathological characteristics and
patient status was analyzed using the chi-square test.
Methylation was evaluated as both a continuous variable
and binary variable. In particular, a cut off of 20% of me-
thylated DNA was used to classify a promoter as hyper-
methylated. Hypermethylation frequencies in NR and R
samples were compared using Fisher’s exact test. The stu-
dent’s T test was used to compare the mean methylation
levels of NR and R samples. Methylation status of multiple
genes was evaluated to determine the presence of hyper-
methylation. Its accuracy (the proportion of R and NR
patients correctly identified by the hypermethylated
profile) in detecting recurrent lesions using the defined
hypermethylation cut off was expressed in terms of
sensitivity (proportion of R patients correctly identified
by the hypermethylated profile) and specificity (proportion
of NR patients correctly identified by the hypermethylated
profile) in relation to the total series. For both indicators,
95% confidence intervals (95% CI) were calculated. Logis-
tic regression was used to analyze the Relative Risks (RR)
and their 95% CI for patient status and methylation
status as dichotomous variables. All analyses were
performed using SAS Statistical software (version 9.3,
SAS Institute, Cary, North Carolina, USA) or Graphpad
Prism software version 5.0d. Statistical significance for
all tests was taken as P < 0.05. The validation of the MS-
MLPA results was done considering the results obtainedA
B
Figure 1 Gene methylation level distribution. A) Hypermethylated gene
disease recurrence. B) Comparison of methylation levels of the three mostby pyrosequencing CpG analysis and IHC considered as
dichotomous variables.
Results
MS-MLPA analysis
Tissue specimens of adenomas from 78 patients were
collected for methylation status analysis (Table 2). Pa-
tients were divided into relapsed (R) or not relapsed
(NR) on the basis of disease recurrence at 5 years of
follow up. In particular, 47 patients (27 with high risk
and 20 with low risk adenomas) did not show disease
recurrence (NR), while 31 patients (16 with high risk and
15 low risk adenomas) developed new colorectal lesions
(R) during this period. No differences in terms of recur-
rence were noted on the basis of pathological classification
(high or low risk adenoma) and no correlation was found
between the grade of dysplasia and development of new
lesions during follow up. Conversely, the site of the first
lesion was significantly related to risk of disease relapse
(P = 0.015).
MS-MLPA analysis was performed for all samples,
obtaining a quantification of methylation status for the en-
tire case series. Two probes (GSTP1 and MLH1 CpG 02)
were discarded from the analysis because they were nega-
tive for methylation (0% methylation level) in 92% and
83% of cases, respectively. We first evaluated the number
of hypermethylated promoters in R and NR patients using
a methylation level of 20% to define a gene promoter ass in the case series subdivided according to the presence or not of
significant genes in R and NR samples.
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higher number of hypermethylated markers (median 6,
range 2–24) than non recurring lesions (median 4, range
0–12) (Figure 1A).
The promoters of three genes (FHIT, MLH1 and ATM)
were found to be hypermethylated in a significantly higher
fraction of adenomas that recurred compared to non
recurring lesions (Figure 1B). Furthermore, TP73 and
BRCA1 promoter hypermethylation were related to recur-
rence, albeit with low statistical significance or borderline
significance, respectively (Table 3).
We then compared the mean methylation levels of gene
promoters in R and NR patients, confirming that MLH1,
ATM and FHIT were significantly differentially methylated
in adenomas on the basis of the presence or not of lesion
recurrence (Figure 2).
In particular, lower levels of methylation were associated
with no recurrence of disease, while substantially higher
values were correlated with relapse. Moreover, other genes
showed differences in terms of methylation alterations. InTable 3 Frequency of promoter hypermethylation in
patients with recurrent or non recurrent disease
Gene ID % R % NR Overall series P
(Total = 31) (Total = 47) (Total = 78)
FHIT 38.71 (12/31) 2.13 (1/47) 16.67 (13/78) 3.1E-05
MLH1 25.81 (8/31) 2.13 (1/47) 11.54 (9/78) 0.002
ATM 22.58 (7/31) 2.13 (1/47) 10.26 (8/78) 0.006
TP73 35.48 (11/31) 12.77 (6/47) 21.79 (17/78) 0.025
BRCA1 9.68 (3/31) 0.00 (0/47) 3.85 (3/78) 0.059
CHFR 29.03 (9/31) 10.64 (5/47) 17.95 (14/78) 0.068
IGSF4 12.90 (4/31) 2.13 (1/47) 6.41 (5/78) 0.078
ESR1 70.97 (22/31) 85.11 (40/47) 79.49 (62/78) 0.158
DAPK1 22.58 (7/31) 10.64 (5/47) 15.38 (12/78) 0.203
CDKN2B 45.16 (14/31) 29.79 (14/47) 35.90 (28/78) 0.228
RASSF1 CpG1 41.94 (13/31) 29.79 (14/47) 34.62 (27/78) 0.333
RASSF1 CpG2 12.90 (4/31) 6.38 (3/47) 8.97 (7/78) 0.427
HIC1 16.13 (5/31) 8.51 (4/47) 11.54 (9/78) 0.471
CDKN2A 22.58 (7/31) 14.89 (7/47) 17.95 (14/78) 0.548
CASP8 6.45 (2/31) 2.13 (1/47) 3.85 (3/78) 0.560
CDH13 80.65 (25/31) 74.47 (35/47) 76.92 (60/78) 0.592
CD44 3.23 (1/31) 8.51 (4/47) 6.41 (5/78) 0.643
BRCA2 12.90 (4/31) 8.51 (4/47) 10.26 (8/78) 0.706
RARB 48.39 (15/31) 44.68 (21/47) 46.15 (36/78) 0.818
APC 45.16 (14/31) 48.94 (23/47) 47.44 (37/78) 0.819
TIMP3 38.71 (12/31) 36.17 (17/47) 37.18 (29/78) 1.000
CDKN1B 9.68 (3/31) 8.51 (4/47) 8.97 (7/78) 1.000
VHL 6.45 (2/31) 6.38 (3/47) 6.41 (5/78) 1.000
PTEN 3.23 (1/31) 4.26 (2/47) 3.85 (3/78) 1.000
Abbreviations: R recurrent disease, NR non recurrent disease. P-value < 0.05.particular, higher methylation levels of CDKN2B, RASSF1,
CHFR, BRCA2 and IGSF4 were observed in adenomas
that recurred.
Methylation status phenotype and clinical pathological
parameters
Taking these data into account, we evaluated the methy-
lation status, determined on the basis of the presence or
not of hypermethylation in the most significantly altered
gene promoters (Table 4a,b). Analysis of MLH1, ATM
and FHIT genes showed that the presence of hyper-
methylation in at least one of these genes indicated
disease recurrence with 61% sensitivity (95% CI 44–76),
and 94% specificity (95% CI 83–98), with an overall accu-
racy of 81% (95% CI 72–90) (Table 4a). This contrasts with
the conventionally used histopathological classification
which highlighted a similar distribution of recurrence in
high- and low-risk subgroups (Table 2). The integration of
BRCA1 and TP73 markers into the panel of genes did not
increase accuracy when either or both were considered in
methylation status analysis (Table 4b).
Unconditional logistic regression analysis was carried
out to evaluate the capacity of MLH1, ATM and FHIT
gene methylation to predict recurrence. FHIT and MLH1
proved to be independent variables with an RR of recur-
rence of 35.30 (95% CI 4.15-300.06, P = 0.001) and 17.68
(95% CI 1.91-163.54, P = 0.011), respectively. CIMP ana-
lysis showed that hypermethylation of at least 1 of these
gene promoters identified recurring adenomas with 58%
sensitivity and 96% specificity (Table 4c).
Methylation status was not related to age or grade of
dysplasia. Conversely, a higher frequency of MLH1
hypermethylation was associated with site of lesion. In
particular, a higher frequency of methylated MLH1 was
observed in ascending with respect to descending le-
sions (71% and 29%, respectively, P = 0.07).
Validation of MS-MLPA results
Pyrosequencing measures the methylation level of single
promoter CpG sites and is used to confirm the results
from other analytical methods [23].
The average methylation percentage of the same CpG
sites as those used for the MS-MLPA approach was
considered for data analysis (data not shown). This ap-
proach was only utilized for MLH1 and ATM as reliable
results were not obtained for FHIT. For this reason,
FHIT was evaluated by immunohistochemistry. A me-
thylated cut-off of ≥20% was used to discriminate
between the methylated and unmethylated phenotype.
Good concordance was observed between MS-MLPA
and the other two methods used (Table 1). In particular, a
comparison between the MS-MLPA and pyrosequencing
methods showed a 79% (57/72 cases) agreement in samples
for MLH1 and a 73% (56/77cases) agreement for ATM,
Figure 2 Volcano Plot representing the differences in methylation levels between relapsed and non relapsed samples plotted against
their statistical significance for all gene promoters analyzed. The three promoters displaying significantly increased methylation levels in R
samples (two-tailed T test, P < 0.05) are highlighted in the upper right corner. T-test P values of the comparison between methylation levels in
R vs NR samples are shown to the right of the plot.
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and IHC was 84% for FHIT (48/57 cases) (Figure 3). This
validation was not performed on samples for which there
was insufficient biological material.
Conclusions
The adenoma-carcinoma sequence is accepted as the
main pathway for the development of colorectal cancer.Table 4 Number of hypermethylated markers in recurrent les
Sensitivity (%)
(95% CI)
a) FHIT, MLH1, ATM
≥1 61.29 (43.82-76.27)
≥2 22.58 (11.40-39.81)
≥3 6.45 (1.79-20.72)
b) FHIT, MLH1, ATM, TP73, BRCA1
≥1 70.96 (53.41-83.90)
≥2 38.71 (23.73-56.18)
≥3 16.13 (7.09-32.63)
≥4 6.45 (1.79-20.72)
≥5 3.22 (0.57-16.19)
c) FHIT, MLH1
≥1 58.06 (40.77-73.58)
≥2 9.68 (3.35-24.90)
Sensitivity, R patients who were correctly identified by the hypermethylated profile
profile; Accuracy, R patients, correctly identified by the hypermethylated profile, an
the total series; 95% CI, 95% confidence intervals.Although some genetic studies have provided evidence
that CRC can develop in other ways, early stage CRCs
frequently show adenomatous mucosa at the tumor per-
iphery. Foci of different grades of dysplasia, intra-
mucosal carcinoma and invasive cancer have also been
observed in pre-neoplastic lesions, indicating a potential
relationship between these different stages of colorectal
lesions [7,17]. A high number of adenomas are nowions
Specificity (%) Accuracy (%)
(95% CI) (95% CI)
93.61 (82.84-97.81) 80.76 (72.02-89.52)
100 (92.44-100) 69.23 (58.99-79.47)
100 (92.44-100) 62.82 (52.09-73.55)
85.11 (72.31-92.59) 79.49 (70.53-88.45)
95.74 (85.75-98.83) 73.08 (63.24-82.92)
100 (92.44-100) 66.66 (56.21-77.13)
100 (92.44-100) 62.82 (52.09-73.55)
100 (92.44-100) 61.53 (50.74-72.34)
95.74 (85.75-98.83) 80.77 (72.02-89.52)
100 (92.44-100) 64.10 (53.45-74.75)
; Specificity, NR patients who were correctly identified by the hypermethylated
d NR patients, correctly identified by the hypermethylated profile, divided by
Figure 3 IHC staining of FHIT protein in adenoma samples. A) High cytoplasmic staining in 85% of colonic glands (grade 3+), a small fraction
of glands (15%-20%) showing low intensity staining (grade 2+). Magnification 2.5 ×. B) High cytoplasmic staining in 85% of colonic glands (grade
3+). Magnification 20×. C) Medium cytoplasm staining in 80% of colonic glands (grade 2+). Magnification 20×. D) Low cytoplasmic staining in
60% of colonic glands; 40%, grade 1+ and 20%, grade 2+. Magnification 2.5×. E) Negative cytoplasmic staining of colonic glands.
Magnification 2.5 x.
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routine colorectal cancer screening, but little informa-
tion is available on the effective risk of recurrence in
these patients.
For this purpose we selected a series of pre-neoplastic
lesions classified histologically as high or low risk
lesions from patients with a different clinical history.
No statistically significant differences were found be-
tween adenomas classified as low risk and those classed
as high risk with respect to recurrence during the 5-
year follow up. Such data indicate that histopathological
classification alone is insufficient to plan an adequate
follow up of these patients. Moreover, grade of dysplasia,
polyp size and other morphological parameters do not
appear to be useful for predicting clinical evolution and
therefore for organizing adequate patient surveillance.
Although defined molecular subtypes of CRC exist, the
molecular subgroups of CRC cannot be accurately distin-
guished histologically or clinically at this time [24].
Conversely, the results from the methylation profile
analyzed in this study indicate that a molecular approach
is capable of accurately predicting recurrence. In par-
ticular, we identified three genes (MLH1, ATM and
FHIT) differentially methylated in adenomas that
recurred during the five-year follow up. The association
between the methylation of these three genes and the
higher aggressiveness of pre-neoplastic lesions may be
attributable to their biological functions. In fact, MLH1and ATM genes play a key role in DNA detection and
repair systems and their inactivation may cause genomic
DNA to become more unstable and error-prone,
increasing the risk of transformation.
The MLH1 protein is involved in the DNA mismatch
repair system (MMR) and methylation of this gene has
been observed in CRC, especially in tumors characterized
by MSI, a molecular marker of the presence of defective
MMR [25,26]. The ATM protein, a serine/threonine
kinase involved in DNA double-strand break repair, is also
involved in DNA repair and its inactivation is a highly
destabilizing event for the cell, promoting the progression
of neoplastic disease [27,28]. It is interesting to note that
MLH1 is an independent variable, despite the molecular
interaction between MLH1 and ATM in regulating DNA
repair. This suggests that concurrent inactivation of both
genes may also be important in cancer development.
FHIT, a tumor suppressor gene involved in numerous
important mechanisms associated with cell cycle response
to stress signals and DNA replication control, is another
independent variable [29]. Wali reported that the FHIT
gene loses its ability to produce its specific protein in the
early stages of lung, head and neck, esophageal, colorectal,
breast, and cervical cancer [30]. The diminution or loss of
FHIT protein expression appears to be influenced by the
extensive promoter methylation program manifested in
CIMP-high CRC cases [31]. TP73 and BRCA1 genes, both
related to a higher risk of recurrence, are also involved
Rengucci et al. Journal of Experimental & Clinical Cancer Research 2014, 33:65 Page 9 of 10
http://www.jeccr.com/content/33/1/65in cell cycle control and DNA repair. In particular, TP73
is a homolog of TP53 tumor suppressor gene, known to
be involved in the regulation of cell proliferation and
apoptosis [32-34], while BRCA1 represents a key regula-
tor in the repair of double-stranded DNA breaks
[26,35]. In Huang et al.’s 2010 study on 110 stage I to IV
CRC patients, TP73 and BRCA1 were identified from a
panel of 15 radiation-related genes as prognosis-related
markers on the basis of their significant correlation with
clinical prognostic variables [36].
In our study, methylation status analysis of a combi-
nation of the three most significant genes (MLH1, ATM,
FHIT) confirmed that they could be used to accurately
identify patients at a higher risk of recurrence. Moreover,
it is worthy of note that these genes (MLH1, ATM, FHIT,
TP73 and BRCA1) were not among those most frequently
methylated in our case series, suggesting that the risk of
recurrence is related to specific molecular characteristics.
In fact, higher aberrant methylation (more than 70% of
cases with methylation levels higher than 20%) was noted
for ESR1 and CDH13, which are not associated with a risk
of recurrence. ESR1 has been shown to occur in histologi-
cally normal colon epithelium in an age dependent fashion
[16,37], CDH13 is also frequently methylated in CRC and
seems to be correlated with the adenoma-carcinoma tran-
sition, like other genes with methylation frequencies > 30%
(CDKN2B, RASSF1, RARB, APC and TIMP3). Although
these genes are probably related to the first step of colorec-
tal transformation, they do not determine a molecular con-
dition of “general colorectal instability” capable of increasing
the risk of normal epithelial cell transformation. The high
frequency of promoter hypermethylation of these genes
confirms previously published literature data [37,38].
The strength of our study lies in the fact that the MS-
MLPA technique has the advantage of requiring a small
quantity of DNA and has been shown to work well in
FFPE samples [39]. However, it is also somewhat limited
due to the small case series (5-year follow up records are
not easily obtained in this patient setting) and to the
heterogeneity of the cell population. Laser micro-dissection
rather them manual macro-dissection would provide more
material that is pure enough for analysis. Furthermore,
when using an MS-MLPA validation approach, it must be
remembered that, unlike pyrosequencing, MS-MLPA does
not require bisulphate conversion and that it does not
quantify the presence of protein, as does IHC.
In conclusion, a more extensive analysis is needed to
confirm these preliminary data, our results would none-
theless seem to indicate that a classification based on
molecular parameters could more accurately select
patients at high risk of recurrence. These methylation
profiles could also provide important information on the
aggressiveness of the lesion and on disease evolution,
useful elements when planning tailored follow up.Abbreviations
CRC: Colorectal cancer; FAP: Familial adenomatous polyposis;
CIN: Chromosomal instability; MSI: Microsatellite instability; CIMP: CpG island
methylator phenotype; MS-MLPA: Methylation-specific multiplex ligation
probe analysis; dNTPs: Deoxynucleoside 5-triphosphates; FFPE: Formalin fixed
paraffin-embedded; R: Relapsed; NR: Not relapsed; 95% CI: 95% confidence
interval; RR: Relative risks; MMR: Mismatch repair; IHC: Immunohistochemistry.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CR and DC conceived and designed the study. MZ, GDM, MMT and GF
carried out the immunohistochemistry assay and performed the
pyrosequencing and MS-MLPA analyses. ACG and LS were responsible for
patient recruitment. LS and MP interpreted the immunohistochemistry
results. ES, CZ and CM performed the statistical analyses. CR, DC, GDM,
MZ, GF and ES drafted the manuscript. DA and WZ reviewed the
manuscript for important intellectual content. All authors read and
approved the final manuscript.
Acknowledgements
The authors thank Ursula Elbling for editing the manuscript and Sara
Bravaccini for technical support. They also thank Gianmarco Musciano of
Diatech Pharmacogenetics, Jesi (AN), Italy, for his advice and contribution to
the development of the pyrosequencing assay.
Author details
1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la
Cura dei Tumori (IRST) IRCCS, Meldola, Italy. 2Department of Medical
Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
(IRST) IRCCS, Meldola, Italy. 3Unit of Biostatistics and Clinical Trials, Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,
Meldola, Italy. 4National Institute of Molecular Genetics, Milan, Italy.
5Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy. 6Pathology Unit,
Santa Maria delle Croci Hospital, Ravenna, Italy.
Received: 30 April 2014 Accepted: 17 July 2014
Published: 5 August 2014
References
1. Jass JR: Classification of colorectal cancer based on correlation of clinical,
morphological and molecular features. Histopathology 2007, 50:113–130.
2. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med
2003, 348:919–932.
3. Rustgi AK: The genetics of hereditary colon cancer. Genes Dev 2007,
21:2525–2538.
4. Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, Van Ballegooijen M,
Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD:
Colonoscopic polypectomy and long-term prevention of colorectal-cancer
deaths. N Engl J Med 2012, 366:687–696.
5. Simunic M, Perkovic N, Rosic-Despalatovic B, Tonkic A, Ardalic Z, Titlic M,
Maras-Simunic M: Colonoscopic polypectomies and recommendations on
the colonoscopy follow-up intervals depending on endoscopic and
histopathological findings. Acta Inform Med 2013, 21:166–169.
6. Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011,
6:479–507.
7. Ahnen DJ: The American College of Gastroenterology Emily Couric
Lecture–the adenoma-carcinoma sequence revisited: has the era of
genetic tailoring finally arrived? Am J Gastroenterol 2011, 106:190–198.
8. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683–692.
9. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer
2004, 4:143–153.
10. Zitt M, Zitt M, Müller HM: DNA methylation in colorectal cancer–impact
on screening and therapy monitoring modalities? Dis Markers 2007,
23:51–71.
11. Kondo Y, Issa JP: Epigenetic changes in colorectal cancer. Cancer
Metastasis Rev 2004, 23:29–39.
12. De Maat MF, van de Velde CJ, van der Werff MP, Putter H, Umetani N,
Klein-Kranenbarg EM, Turner RR, Van Krieken JHJM, Bilchik A, Tollenaar
RAEM, Hoon DSB: Quantitative analysis of methylation of genomic loci in
Rengucci et al. Journal of Experimental & Clinical Cancer Research 2014, 33:65 Page 10 of 10
http://www.jeccr.com/content/33/1/65early-stage rectal cancer predicts distant recurrence. J Clin Oncol 2008,
26:2327–2335.
13. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M,
Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A,
Niemann S, Foekens JA, Lesche R, Martens JW: DNA methylation markers
predict outcome in node-positive, estrogen receptor-positive breast cancer
with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2009,
15:315–323.
14. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, Tos AG,
Merletti F: Promoter methylation in APC, RUNX3, and GSTP1 and
mortality in prostate cancer patients. J Clin Oncol 2009, 27:3161–3168.
15. Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M,
Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezio Sardo A, Bifulco G,
Nappi C, Bufo P, Guida M, De Rosa G, Abbruzzese A, Caraglia M, Pannone G:
Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of
a uterine field cancerization. Cancer Biol Ther 2011, 12:447–457.
16. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004,
4:988–993.
17. Rashid A, Issa JPJ: CpG island methylation in gastroenterologic neoplasia:
a maturing field. Gastroenterology 2004, 127:1578–1588.
18. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA,
Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L,
Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R,
Laird PW: CpG island methylator phenotype underlies sporadic
microsatellite instability and is tightly associated with BRAF mutation in
colorectal cancer. Nat Genet 2006, 38:787–793.
19. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Kim M,
Young J, Whitehall VL, Leggett BA, Laird PW: Analysis of the association
between CIMP and BRAF in colorectal cancer by DNA methylation
profiling. PLoS One 2009, 4:e 8357.
20. Ji W, Hernandez R, Zhang XY, Qu GZ, Frady A, Varela M, Ehrlich M:
DNA demethylation and pericentromeric rearrangements of
chromosome 1. Mutat Res 1997, 379:33–41.
21. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D,
Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR: The CpG Island
methylator phenotype and chromosomal instability are inversely correlated
in sporadic colorectal cancer. Gastroenterology 2007, 132:127–138.
22. Leong KJ, Wei W, Tannahill LA, Caldwell GM, Jones CE, Morton DG,
Matthews GM, Bach SP: Methylation profiling of rectal cancer identifies
novel markers of early-stage disease. Br J Surg 2011, 98:724–734.
23. Moon JW, Lee SK, Lee JO, Kim N, Lee YW, Kim SJ, Kang HJ, Kim J, Kim HS,
Park SH: Identification of novel hypermethylated genes and
demethylating effect of vincristine in colorectal cancer. J Exp Clin Cancer
Res 2014, 33:4.
24. Bardhan K, Liu K: Epigenetics and colorectal cancer pathogenesis.
Cancers (Basel) 2013, 5:676–713.
25. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM,
Kolodner R: Methylation of the hMLH1 promoter correlates with lack of
expression of hMLH1 in sporadic colon tumors and mismatch
repair-defective human tumor cell lines. Cancer Res 1997, 57:808–811.
26. Fu D, Calvo JA, Samson LD: Balancing repair and tolerance of DNA
damage caused by alkylating agents. Nat Rev Cancer 2012, 12:104–120.
27. Lavin MF: Ataxia-telangiectasia: from a rare disorder to a paradigm for
cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9:759–769.
28. Shiloh Y: ATM and related protein kinases: safeguarding genome
integrity. Nat Rev Cancer 2003, 3:155–168.
29. Huebner K, Saldivar JC, Sun J, Shibata H, Druck T: Hits, Fhits and Nits:
beyond enzymatic function. Adv Enzyme Regul 2011, 51:208–217.
30. Wali A: FHIT: doubts are clear now. Scientific World Journal 2010, 10:1142–1151.
31. Al-Temaimi RA, Jacob S, Al-Ali W, Thomas DA, Al-Mulla F: Reduced FHIT
expression is associated with mismatch repair deficient and high CpG
island methylator phenotype colorectal cancer. J Histochem Cytochem
2013, 61:627–638.
32. Portela A, Esteller M: Epigenetic modifications and human disease.
Nat Biotechnol 2010, 28:1057–1068.
33. Herreros-Villanueva M, Muñiz P, García-Girón C, Cavia-Saiz M, Del Corral
MJ: TAp73 is one of the genes responsible for the lack of response to
chemotherapy depending on B-Raf mutational status. J Transl Med
2010, 8:15.
34. Allocati N, Di Ilio C, De Laurenzi V: p63/p73 in the control of cell cycle and
cell death. Exp Cell Res 2012, 318:1285–1290.35. Murphy CG, Moynahan ME: BRCA gene structure and function in tumor
suppression: a repair-centric perspective. Cancer J 2010, 16:39–47.
36. Huang MY, Wang JY, Chang HJ, Kuo CW, Tok TS, Lin SR: CDC25A, VAV1,
TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation
response in colorectal cancer. Oncol Rep 2011, 25:1297–1306.
37. Lao VV, Grady WM: Epigenetics and colorectal cancer. Nat Rev
Gastroenterol Hepatol 2011, 8:686–700.
38. Noda H, Kato Y, Yoshikawa H, Arai M, Togashi K, Nagai H, Konishi F, Miki Y:
Frequent involvement of ras-signalling pathways in both polypoid-type
and flat-type early-stage colorectal cancers. J Exp Clin Cancer Res 2006,
25(2):235–242.
39. Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F,
Zingaretti C, Silvestrini R, Amadori D, Zoli W: DNA Methylation profiles
as predictors of recurrence in non muscle invasive bladder cancer: an
MS-MLPA approach. J Exp Clin Cancer Res 2013, 32:94.
doi:10.1186/s13046-014-0065-x
Cite this article as: Rengucci et al.: Promoter methylation of tumor
suppressor genes in pre-neoplastic lesions; potential marker of
disease recurrence. Journal of Experimental & Clinical Cancer Research
2014 33:65.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
